Summary
Stryker Corporation reported solid revenue growth for the nine months ending September 29, 2021, with net sales increasing by 23.0% to $12.4 billion, compared to the same period in 2020. This growth was driven by a broad-based increase in unit volume across all product categories and was further boosted by acquisitions, which contributed 6.8% to the reported sales increase. While net earnings for the nine months rose to $1.33 billion, up from $1.03 billion in the prior year, the diluted earnings per share saw a decrease in the third quarter due to increased expenses and charges. The company's performance in the third quarter showed a 11.3% increase in net sales, reaching $4.16 billion. However, operating income declined significantly compared to the prior year, largely influenced by recall charges, increased research and development, and selling, general, and administrative expenses, including a notable $105 million impairment charge related to China's volume-based procurement programs. Despite these headwinds, Stryker maintained a strong financial position with substantial liquidity and a robust credit facility, positioning it to navigate ongoing market dynamics.
Financial Highlights
50 data points| Revenue | $4.16B |
| Cost of Revenue | $1.52B |
| Gross Profit | $2.64B |
| R&D Expenses | $306.00M |
| SG&A Expenses | $1.60B |
| Operating Expenses | $2.07B |
| Operating Income | $574.00M |
| Net Income | $438.00M |
| EPS (Basic) | $1.17 |
| EPS (Diluted) | $1.14 |
| Shares Outstanding (Basic) | 377.10M |
| Shares Outstanding (Diluted) | 382.70M |
Key Highlights
- 1Net sales for the nine months ended September 29, 2021, increased by 23.0% to $12.41 billion, compared to $10.09 billion in the same period of 2020, driven by organic growth and acquisitions.
- 2Third-quarter 2021 net sales grew 11.3% to $4.16 billion, indicating continued top-line momentum, although operating income saw a year-over-year decrease.
- 3The company recorded an impairment charge of $105 million in the third quarter related to China's volume-based procurement programs, impacting profitability.
- 4Recall charges amounted to $98 million for the nine months of 2021, primarily related to previously disclosed hip stem recalls.
- 5Stryker strengthened its liquidity by entering into a new $2.25 billion revolving credit agreement in October 2021, replacing its previous facility.
- 6Despite a decrease in reported net earnings per diluted share for the third quarter, adjusted net earnings per diluted share showed an increase, highlighting operational resilience.
- 7The Orthopaedics segment experienced significant growth in the nine months of 2021, with net sales up 35.2%, largely due to the acquisition of Wright Medical.